Synbio startup GRObio gets $25M to work with new building blocks for protein drugs


Harvard University spinout GRO Biosciences has technology offering the potential for protein therapies that are safer and more effective than currently available biologic drugs. The startup’s research is now backed by $25 million, a Series A financing round whose investors include the venture arm of Bayer.

Leave a Reply